Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020)
Alx Oncology Holdings (ALXO) posted Preferred Stock Liabilities of $175.0 million for Q2 2020, little changed sequentially from $175.0 million in Q1 2020, and up 148.77% YoY from $70.4 million in Q3 2019.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported Preferred Stock Liabilities for 2 years, with the latest figure at $175.0 million in Q2 2020.
- Quarterly Preferred Stock Liabilities rose 148.77% year-over-year to $175.0 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $175.0 million (up 148.77% YoY) and the FY2019 annual result came in at $70.4 million, up 15.48% from the prior year.
- Preferred Stock Liabilities steadied at $175.0 million in Q2 2020 per ALXO's latest filing, from $175.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $175.0 million in Q1 2020 and troughed at $70.4 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Alx Oncology Holdings | 274.67 Mn | 274.67 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 175.04 Mn |
| Mar 31, 2020 | 175.04 Mn |
| Dec 31, 2019 | 70.36 Mn |
| Sep 30, 2019 | 70.36 Mn |
| Jun 30, 2019 | 70.36 Mn |